ArticleDiscover oncology2026
Anti-CD38 targeted carfilzomib-loaded hybrid nanocomposites for multiple myeloma therapy: cytotoxicity and biodistribution.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carfilzomib (CFZ), a second-generation proteasome inhibitor, offers potent activity against multiple myeloma (MM) but suffers from rapid clearance, short half-life (< 30 min), and poor in vivo stability, which limit its therapeutic efficacy. To overcome these challenges, we designed a targeted nanotherapeutic system i.e., anti-CD38 monoclonal antibody (mAb) functionalized carfilzomib loaded PCL nanocomposites (Ab-CFZ-PCL-NPs). Nanocomposites were fabricated using a nanoprecipitation method within a quality by design (QbD) framework and characterized by Fourier transformed infrared (FTIR), dynamic light scattering (DLS), and entrapment efficiency studies. DLS analysis showed that the mean hydrodynamic diameter and PDI of CFZ-PCL-NPs were 103.6 ± 0.134 nm and 0.113 ± 0.177, respectively. In contrast, the Anti-CD38 conjugated nanocomposites exhibited a significantly larger size of 189.9 ± 0.321 nm (p < 0.05, Student’s t-test) and a PDI of 0.135 ± 0.126, confirming the successful surface deposition of the Anti-CD38 antibody. The in vitro drug release demonstrated sustained drug diffusion at physiological pH(7.4) with 91.12 ± 1.058% DR (up to 10 days) while a significantly faster drug diffusion (96.78 ± 0.942% (up to 4 days) was observed at tumor stimulating pH(5.5) corroborating a pH responsively behavior of nanosystem .Antibody conjugation significantly improved cellular uptake (> 85%), cytotoxicity (> 90%) in multiple myeloma cells (MM cells), and high tumor growth inhibition(> 85%) compared to non-conjugated nanocomposites. This work highlights the novelty of combining proteasome inhibition with anti-CD38 targeting in a single nano-formulation, offering prolonged drug retention, improved tumor-specific delivery, and reduced systemic limitations of CFZ. The Ab-CFZ-PCL-NPs establish a promising theragnostic platform for advancing precision therapies in multiple myeloma beyond conventional nanoparticle approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.